Intramuscular human interferon-beta injections in treatment of condylomata acuminata.
A two-part study was done to assess the value of human fibroblast interferon (IFN-beta) in the treatment of condylomata acuminata. The first part was an open study of different IFN-beta preparations, which showed that intramuscular injection was the most suitable mode of administration of IFN-beta. In the double-blind placebo section 22 patients were given injections of 2 X 10(6) units IFN-beta or placebo for 10 consecutive days and followed up for 3 months. In 9 of the 11 in the IFN-beta group and 2 in the placebo group lesions disappeared from about 5 weeks after completion of the course of injections. After 3 months 8 of the non-responders were given a course of IFN-beta and all responded to treatment. None of those who had responded has had a recurrence, the disease-free period now being 12 months. Changes in (2'-5')oligo A synthetase levels in white blood cells confirm that intramuscular injections of IFN-beta produce a systemic response.
D015088:2',5'-Oligoadenylate Synthetase / Q000097:blood; D000293:Adolescent; D000328:Adult; D000818:Animals; D002986:Clinical Trials as Topic; D003218:Condylomata Acuminata / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D005833:Genital Neoplasms, Female / Q000628:therapy*; D005834:Genital Neoplasms, Male / Q000628:therapy*; D006801:Humans; D007273:Injections, Intramuscular; D007370:Interferon Type I / Q000008:administration & dosage*; D007962:Leukocytes / Q000201:enzymology; D008297:Male; D027383:Papillomaviridae / Q000254:growth & development; D011897:Random Allocation; D014412:Tumor Virus Infections / Q000628:therapy; D014779:Virus Replication / Q000187:drug effects
D007370:Interferon Type I; D015088:2',5'-Oligoadenylate Synthetase